Literature DB >> 12670950

The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport.

Pijun Wang1, Richard B Kim, J Roy Chowdhury, Allan W Wolkoff.   

Abstract

A recent study (Cui, Y., Konig, J., Leier, I., Buchholz, U., and Keppler, D. (2001) J. Biol. Chem. 276, 9626-9630) suggests that human OATP2 (SLC21A6), also known as OATP-C and LST1, mediates hepatic bilirubin transport. Because of methodologic concerns, this study was designed to examine this issue using a bilirubin transport assay that was validated in overnight cultured rat hepatocytes. These studies showed that cultured rat hepatocytes transported bilirubin with kinetics virtually identical to the transport of sulfobromophthalein. This assay was then used to quantify bilirubin transport by HeLa cells that had been stably transfected with OATP2 under regulation of a metallothionein promoter. Immunoblot analysis revealed abundant expression of OATP2 after incubation of cells for 48 h in zinc, whereas uninduced cells had no expression of this protein. In OATP2-expressing (zinc-induced) HeLa cells at 37 degrees C, the uptake of [35S]sulfobromophthalein was substantial (51.6 +/- 16.5 pmol/15 min/mg protein, n = 5) with little cell-associated ligand in non-expressing (uninduced) cells (0.54 +/- 0.16 pmol/15 min/mg protein, n = 5, p < 0.002). In contrast, there was no difference (p > 0.2) in cell-associated [3H]bilirubin in induced (OATP2-expressing) as compared with uninduced cells (11.25 +/- 3.02 pmol/15 min/mg protein versus 9.15 +/- 1.68 pmol/min/mg protein, respectively, n = 5) We obtained similar results in OATP2-transfected HEK293 cells that were used in the original report. The existence of a bilirubin transporter has been an important field of investigation for many years. Although the current study indicates that a role for OATP2 in hepatocyte bilirubin transport is unlikely, it provides new and sensitive tools that can be adapted to examine the function of putative bilirubin transporters in the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670950     DOI: 10.1074/jbc.M301100200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.

Authors:  Jayanta Roy-Chowdhury; Namita Roy-Chowdhury; Irving Listowsky; Allan W Wolkoff
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

Review 2.  Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.

Authors:  Paul D Berk
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

3.  Association of neonatal hyperbilirubinemia in breast-fed infants with UGT1A1 or SLCOs polymorphisms.

Authors:  Hiroko Sato; Toshihiko Uchida; Kentaro Toyota; Tomohiro Nakamura; Gen Tamiya; Miyako Kanno; Taeko Hashimoto; Masashi Watanabe; Kuraaki Aoki; Kiyoshi Hayasaka
Journal:  J Hum Genet       Date:  2014-11-13       Impact factor: 3.172

Review 4.  Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion-transporting polypeptides.

Authors:  Wooin Lee; Jeong-Min Ha; Yuichi Sugiyama
Journal:  J Biol Chem       Date:  2020-10-13       Impact factor: 5.157

Review 5.  Organic anion uptake by hepatocytes.

Authors:  Allan W Wolkoff
Journal:  Compr Physiol       Date:  2014-10       Impact factor: 9.090

6.  Development of a high-affinity inhibitor of the prostaglandin transporter.

Authors:  Yuling Chi; Jaeki Min; Jean-Francois Jasmin; Michael P Lisanti; Young-Tae Chang; Victor L Schuster
Journal:  J Pharmacol Exp Ther       Date:  2011-08-17       Impact factor: 4.030

7.  PharmGKB very important pharmacogene: SLCO1B1.

Authors:  Connie Oshiro; Lara Mangravite; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

Review 8.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

9.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.

Authors:  Richard H Ho; Leena Choi; Wooin Lee; Gail Mayo; Ute I Schwarz; Rommel G Tirona; David G Bailey; C Michael Stein; Richard B Kim
Journal:  Pharmacogenet Genomics       Date:  2007-08       Impact factor: 2.089

Review 10.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.